Citi Downgrades ARIAD Pharmaceuticals (ARIA) to Sell; Potential Negatives Outweigh Positives
Tweet Send to a Friend
Citi downgraded ARIAD Pharmaceuticals (NASDAQ: ARIA) from Neutral to Sell but raises its price target from $2.50 to $5.50, citing ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
